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INTRODUCTION
Metastatic human prostate cancer (PC) is commonly treated by hormone, radiation, and/or chemotherapy. Inevitably, these patients will eventually relapse and develop androgen-independent (AI) disease with osseous metastasis. Since no effective therapy is presently available for the treatment of PC metastasis, we are developing a novel gene therapy modality for hormonal refractory prostate cancer based on a prostate-specific chemic promoter, PSES, generated in collaboration with Dr. Chinghai Kao, a coinvestigator of this project. In this study, we proposed to generate a herpes simplex virus thymidine kinase (TK) armed prostate restricted replicative adenovirus (PRRA) to treat AI prostate cancers. Specific Aim 1 intended to simplify and combine the most important enhancer elements from PSA (prostate specific antigen) and PSMA (prostate specific membrane antigen) enhnacers/promoters to generate a strong and simple prostate-specific chimeric enhancer, sPSES. Specific Aim 2 would test whether sPSES retained prostate specific activity in an adenoviral vector. Specific Aim 3 would test whether sPSES could control adenoviral replication by controlling adenovirus E1a and E1b expression, and investigate how replication competent adenovirus eradicated prostate cancers by micro positron emission tomography (microPET) imaging. Figure 2 . Sequences of PSME located in the third intron in the PSMA gene (FOLH1). PSME is characterized by the repeat sequence (marked by underline and bold) and an Alu sequence (marked by lower case). Several potential transcription factor binding sites, such as AP-1, AP-3, and SRY/SOX, are indicated. (marked by italic in Figure 2 ) of PSME with simple AP-3 binding site. Table 1 ). h. 
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KEY RESEARCH ACCOMPLISHMENTS

4.
Successfully synthesize 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) for microPET imaging Ad-IU-1 activity.
5.
Ad-IU-1 demonstrated a prostate specific replication and killing activity.
6.
The tumor killing activity of Ad-IU-1 is significantly enhanced by GCV as hypothesized originally.
REPORTABLE OUTCOMES
Some of the results of this study have been published. 
CONCLUSIONS
We have successfully shortened PSES as planned and demonstrated the prostate specific activity of the shortened form of PSES, m6. We made a prostate restricted replicative adenovirus-armed with TK, Ad-IU-1, as proposed. Ad-IU-1 replicated efficiently in PSA/PSMA positive prostate cancer cells. Its replication efficiency was significantly attenuated in PSA/PSMA negative cells. Both in vitro and in vivo tumor-killing activities of Ad-IU-1 are significantly enhanced by the prodrug GCV as our original hypothesis. We are on the process of conducting a toxicology studies to prepare Ad-IU-1 for clinical investigation. At the same time, we are improving Ad-IU-1 by replacing it TK gene with a more powerful suicide gene, FCYttk. 
Introduction
Prostate cancer is still remains the leading cancer diagnosis in men. The incidence of prostate cancer is age-dependent and has steadily increased over the last several decades 1 .
Localized prostate cancer can be managed effectively with surgery or radiation, while advanced and metastatic disease eventually progresses to an androgen-independent (AI) state with limited treatment options. The aging population of men with an increasing prostate cancer incidence combined with an absence of successful therapies for advanced disease require the development of novel therapies.
Tumor-specific suicide gene therapy using a tissue-specific promoter is a rational treatment strategy for prostate cancer 2 , 3 . Herpes simplex virus thymidine kinase (HSV-TK)-based suicide gene therapy has been used to target prostate cancer for over a decade [4] [5] [6] . The prodrug ganciclovir (GCV) is phosphorylated by HSV-TK to its monophosphate form, which is rapidly converted to di-and triphosphate forms by cellular kinases, the latter of which is toxic to cells.
The GCV-triphosphate is incorporated into DNA during cell division, causing single-strand DNA breaks and inhibition of DNA polymerase 7 . Prior preclinical studies have demonstrated that HSV-TK/prodrug-based suicide gene therapy inhibited the growth of mouse and human prostate cancer cells in vivo 8 . Clinical studies using the HSV-TK/GCV system for the treatment of prostate cancer have also shown the effectiveness of this suicide gene therapy strategy 9 .
However, previous HSV-TK/GCV studies suffered from inefficient gene transduction rates in vivo. We recently develop a prostate-specific chimeric enhancer, PSES, by combining enhancers from PSA and PSMA genes. Prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA) are prostate-specific biomarkers that are expressed by the majority of prostate tumors and non-cancerous epithelium. The main prostate-specific enhancer activity of the PSA enhancer core was located in a 189 bp region called AREc3, and the main prostate-specific enhancer activity of the PSMA enhancer core was located in a 331 bp region called PSME(del2).
The combination of these two regulatory element, AREc3 and PSME(del2), called PSES, showed high activity specifically in PSA/PSMA-positive prostate cancer cells, regardless of androgen status 17 . This PSES promoter has been used to control the replication of a PRRA, which demonstrated prostate-specific replication and therapeutic efficacy both in vitro and in vivo 18 . In this study, we developed a novel HSV-TK-armed replicative adenovirus, AdIU1, using the PSES promoter to drive the expression of adenoviral E1a, E1b and E4 genes in addition to HSV-TK.
AdIU1 demonstrated its selective cytotoxicity toward androgen-independent (AI) PSA/PSMAexpressing prostate cancer both in vitro and in vivo. Construction of the prostate-restricted replicative andenovirus (PRRA), AdIU1.
Materials and Methods
Cells and Cell
The construction of the backbone for AdIU1, AdE4PSESE4, was described previously 18 .
To construct AdIU1, the CMV-EGFP expression cassette in AdE4PSESE1a was replaced by a 
PSES-HSV-TK expression cassette. HSV-TK and
Western blot analyses for AdIU1
For Ad5E1a and HSV-TK protein detection, 1x 10 6 cells plated in 60 mm dishes were infected with 1000 v.p/cell of AdIU1. Cells were harvested and lysed in 100 µL of cell lysis buffer (50 mM Tris-HCl (pH 7.4), 1 % NP-40, 0.25 % Na-deoxycholate, 150 mM NaCl, 1 mM PMSF, 1 µg/mL Aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 1 mM Na 3 VO 4 , and 1 mM 
Dose-dependent in vitro cell killing assay
CWR22rv and DU145 cells were seeded onto 24-well plates at a density of 1.5 x 10 5 or 1 x 10 4 cells/well respectively. After 24 hr, the cells were infected with 0.1-1000 vp per cell of AdIU1 or AdE4PSESE1a. 24 hr after infection, the media were removed and replaced by fresh media with or without GCV (10 µg/ml). Media with or without GCV were changed every 2 days. Viable cells were analyzed by crystal violet assay 7 days post-infection.
Time-dependent in vitro killing assay
CWR22rv and DU-145 cells were plated in 24-well plates. Cells were divided into 4 treatment groups, no treatment, AdIU1 (100 vp/cell), GCV, and AdIU1 (100 vp/cell) plus GCV.
The media were changed 24 hrs after infection, and GCV (10 µg/ml) was added 24 hrs after the media change. Cell viability was analyzed at day 1, 3, 5 and 7 by crystal violet assay.
In vivo evaluation of AdIU1 therapy
All animal methods and procedures were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee (IACUC). CWR22rv xenografts were established by injecting 2 x10 6 cells s.c. in the flanks of 6 week-old male, athymic nude mice.
The injected mice were castrated 3 days after cells injection. Mice with similar tumor sizes (3 -5 mm) were divided into four groups receving, AdE4PSESE1a (negative control PRRA), AdE4PSESE1a plus GCV, AdIU1, or AdIU1 plus GCV treatment. 2 x 10 9 v.p. of either AdE4PSESE1a or AdIU1 in 100 µL 1xPBS were injected intratumorally. 5 days after virus injection, GCV (40 mg/kg) was administered i.p. twice-daily for 10 days. Tumor sizes were measured every 5 days, and the following formula was applied to calculate tumor volume, length x width 2 x 0.5236. Mice were sacrificed and tumors harvested for histological examination 30 days after injection.
Histology and Immunohistochemistry
Tumors were harvested, immediately fixed in formalin and embedded in paraffin. The 
Results
Construction of a TK-armed PRRA.
AdIU1 was constructed by replacing the CMV-GFP expression cassette in AdE4PSESE1a
18 with a PSES-HSV-TK expression cassette to extend the therapeutic potential of the PSES-based PRRA (Fig 1) . HER 911E4 cells were transfected with recombinant adenoviral plasmid linearized by Pac I restriction enzyme digestion, and AdIU1 was purified from the harvest viral supernatant.
To assess the prostate-specificity and viral replication efficiency of AdIU1, we performed an in vitro viral replication assay. PSA/PSMA-positive and -negative cells were infected with AdIU1. Viral plaques were observed only in the PSA/PSMA-positive cells (Table   1 ), demonstrating the fact that AdIU1 replication is tightly controlled by PSES and restricted to PSA/PSMA-positive cells. We performed a prodrug sensitivity assay in vitro. Each cell line, CWR22rv, C4-2 and DU-145 were seeded in triplicate in 24-well plates at a density of 2 ×10 4 cells/well and were incubated with increasing concentrations of GCV (0 to 100 µg/ml).
Western blotting analysis of adenovirus
Cell viability was determined after 5 days using crystal violet assay, and a corresponding IC 50 dose was determined for each cell line (data not shown). We determined the optimal GCV treatment dose to be 10 µg/ml.
To evaluate the selective cytotoxicity of AdIU1 and AdE4PSESE1a viruses, we infected each cell line with wide dose ranges (0.1-1000 v.p./cell) of virus, and then treated infected cells with or without GCV (10 µg/ml) (Fig 3) . CWR22rv cell line demonstrated cell growth inhibition at day 7 after AdIU1 exposure, which was significantly enhanced when GCV was administered following AdIU1 infection. The DU-
In vivo growth inhibition of CWR22rv xenograft by AdIU1/GCV
Human prostate CWR22rv xenograft tumors were induced by subcutaneous injection of CWR22rv cells into athymic nude mice. The mice were castrated 3 days after CWR22rv inoculation to test whether AdIU1 or AdE4PSESE1a was able to eliminate AI tumors in a castrated host. After tumor formation, the mice were randomized into 4 groups (AdIU1, AdE4PSESE1a, AdIU1 plus GCV and AdE4PSESE1a plus GCV). The mice were injected intratumorally with AdIU1 or AdE4PSESE1a as a control. Day 0 was the time of virus injection. On day 5, groups receiving GCV treatments were injected with GCV (40 mg/kg) 2 times a day for 10 days. Tumor volumes were measured at the times indicated in Figure 4 .
AdIU1/GCV effectively caused growth delay of CWR22rv xenografts. Light microscopic observation of H&E-stained tumors in mice injected with AdIU1/GCV showed substantial treatment effect (Fig 6) .
We also observed a large number of fibrosis following combined treatment. To compare proliferation between the GCV treatment group and non-treated group, we performed immunohistochemistry using the proliferation antigen, Ki67. We observed no significant difference in proliferation antigen expression between both groups. Also, we observed that all necrotic tumors stained positive for apoptosis by TUNEL assay. Anti-adenovirus type 5
E1a immunohistochemical staining revealed that extensive viral infection existed throughout the AdIU1, AdE4PSESE1a, and AdE4PSESE1a plus GCV treatment group tumors; however, adenovirus staining was absent in the AdIU1 plus GCV treatment group. investigations, prostate-specific enhance sequence (PSES), was developed by locating the minimal sequence, AREc3 and PSME(del2) in AREc and PSME, respectively and placing AREc3
upstream from PSME (del2) 17 . PSES showed high activity specifically in PSA/PSMA-positive and AI prostate cancer cells 18 .
Gene therapy with HSV-TK as a suicide gene has been performed in a variety of tumor models in vitro as well as in vivo. We already showed that both PSA and OC promoters can 
